US 8,524,773 B2 · Utilization of dialkylfumarates

Abstract

The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Claims5

Dependent claims

A method of treating a patient in need of treatment for multiple sclerosis comprising contacting peripheral blood mono-nuclear cells or monocytes of said patient with methyl hydrogen fumarate.

Dependencies are inferred from the claim text.

Facts

Application

13/612,221Filed 12 Sep 2012 · division

Priority

DE 198 53 48719 Nov 1998

Published

US 2013/0004526 A13 Jan 2013

Granted

3 Sep 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

A61K 9/4891
Preparations in capsules, e.g. of gelatin, of chocolate: coated capsules; Multilayered drug free capsule shells
A61K 9/1676
With an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface: having a drug-free core…
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
A61K 9/2027
Organic macromolecular compounds: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, polyacrylates

Family

PCT/EP99/08215Parent of this division · filed 29 Oct 1999

Application10/197,077Parent of this continuation · filed 17 Jul 2002

US 6,509,376 B1Parent of this division · filed 21 Jan 2003

Application11/765,578Parent of this continuation · filed 20 Jun 2007

US 7,320,999 B2Parent of this continuation · filed 22 Jan 2008

Application12/405,665Parent of this continuation · filed 17 Mar 2009

US 7,619,001 B2Parent of this continuation · filed 17 Nov 2009

Application13/040,914Parent of this division · filed 4 Mar 2011

US 7,915,310 B2Parent of this continuation · filed 29 Mar 2011

US 2013/0004526 A1Pre-grant publication · published 3 Jan 2013

Application13/040,914Parent of this continuation

Application09/831,620Parent of this division

Application10/197,077Parent of this division

US 2003/0018072 A1Published application

US 2007/0248663 A1Published application

US 2009/0182047 A1Published application

US 2011/0293711 A1Published application

US 8,759,393 B2Related patent

US 8,524,773 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

13/612,221Filed 12 Sep 2012 · division

Priority

DE 198 53 48719 Nov 1998

Published

US 2013/0004526 A13 Jan 2013

Granted

3 Sep 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

A61K 9/4891
Preparations in capsules, e.g. of gelatin, of chocolate: coated capsules; Multilayered drug free capsule shells
A61K 9/1676
With an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface: having a drug-free core…
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
A61K 9/2027
Organic macromolecular compounds: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, polyacrylates

Family

PCT/EP99/08215Parent of this division · filed 29 Oct 1999

Application10/197,077Parent of this continuation · filed 17 Jul 2002

US 6,509,376 B1Parent of this division · filed 21 Jan 2003

Application11/765,578Parent of this continuation · filed 20 Jun 2007

US 7,320,999 B2Parent of this continuation · filed 22 Jan 2008

Application12/405,665Parent of this continuation · filed 17 Mar 2009

US 7,619,001 B2Parent of this continuation · filed 17 Nov 2009

Application13/040,914Parent of this division · filed 4 Mar 2011

US 7,915,310 B2Parent of this continuation · filed 29 Mar 2011

US 2013/0004526 A1Pre-grant publication · published 3 Jan 2013

Application13/040,914Parent of this continuation

Application09/831,620Parent of this division

Application10/197,077Parent of this division

US 2003/0018072 A1Published application

US 2007/0248663 A1Published application

US 2009/0182047 A1Published application

US 2011/0293711 A1Published application

US 8,759,393 B2Related patent

US 8,524,773 B2This patent

From the US filing history. Foreign family members aren’t listed.

Utilization of dialkylfumarates

Life of this patent

Abstract

Claims5

Utilization of dialkylfumarates

Life of this patent

Abstract

Claims5